Mild relief at 6 months: Finasteride offers some improvement of CPPS symptoms

Orlando, FL-The 5-alpha-reductase inhibitor finasteride (Proscar)is associated with symptom improvement in men with category IIIA chronicpelvic pain syndrome, say leading prostatitis researchers.

Related Videos

Raymond Xu, MD, discusses Cost Plus Drugs and urogynecologic medications

Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause

Why a personalized approach is key to prolapse and OAB management

Anna Myers, CNP, on the overlap between urological and gynecological conditions

Sarah Ponce discusses pelvic and vulvovaginal pain among medical trainees

Expert offers advice on starting a sexual wellness/aesthetics practice

Expert discusses pelvic pain and vesicovaginal fistula

Dr. Taghechian on her women’s sexual health practice

Expert urges patient education on vaginal estrogen products

Dr. Syan shares her thoughts on SUFU 2024

Related Content

Advertisement

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

Related Content

Drug TherapyFemale Urology

Drug Therapy

|

Female Urology

Advertisement

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.